EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA

Abstract

Three monthly intravitreal bevacizumab injections resulted in significant reduction in central foveal thickness and improvements in BCVA in diabetic macular edema patients. Both 1.25 mg and 2.5 mg seemed to have similar treatment efficacy.